ICMR partners with BBIL to develop indigenous COVID-19 vaccine

WION Web Team
New Delhi, Delhi, India Published: May 09, 2020, 10.34 PM(IST)

ICMR Photograph:( ANI )

Story highlights

The two bodies have started the work on developing the vaccine, with ICMR-NIV providing support to BBIL.

The Indian Council of Medical Research (ICMR) has announced a partnership with Bharat Biotech International Limited (BBIL) on Saturday to develop a vaccine for coronavirus.

The vaccine will be developed using the virus strain isolated at the National Institute of Virology (NIV), Pune.

Also read: Total COVID-19 cases in India cross 56,000-mark; 16539 patients cured

The two bodies have started the work on developing the vaccine, with ICMR-NIV providing support to BBIL.

"The strain has been successfully transferred from NIV to Bharat Biotech International Ltd. (BBIL). Work on vaccine development has been initiated between the two partners. ICMR-NIV will provide continuous support to BBIL for vaccine development. ICMR and BBIL will seek fast-track approval to expedite vaccine development, subsequent animal studies and clinical evaluation of the candidate vaccine," stated the press release.

Dr Y K Gupta is chairing the committee for Evaluation of Research Proposals at ICMR. Earlier today he claimed that the data available to to the officials is not enough to perform clinical study on using Ganga water for treatment of coronavirus.

(With inputs from ANI)

Read in App